Trial
NCT04874194
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
—
Condition
Hematopoietic and Lymphoid Cell Neoplasm
Intervention
Omacetaxine Mepesuccinate
Why stopped
The study terminated early because the company was longer providing the investigational product.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-03